Core Points - The Chinese government is focusing on high-quality health initiatives during the "14th Five-Year Plan," with significant achievements in disease prevention and control [1] - The introduction of HPV vaccination services for eligible girls is a key initiative aimed at protecting women's health [1] Group 1: HPV Vaccination Initiatives - The national health authority is implementing free HPV vaccination services across various regions, with a focus on accessibility and convenience for the public [2] - The HPV vaccine included in the national immunization program is a bivalent vaccine, primarily targeting HPV types 16 and 18, which account for 70% to 80% of cervical cancer cases [2] - Approximately 60% of eligible girls in China are covered by the free vaccination policy, which has been adopted in 18 provinces and several cities [2] Group 2: Domestic Vaccine Development - The domestic bivalent HPV vaccine has proven to be effective and cost-efficient, significantly lowering vaccination costs and facilitating the establishment of a large-scale immunity barrier [3] - The launch of the first domestically developed nine-valent HPV vaccine, "Xinkening 9," marks a significant advancement in cervical cancer prevention, providing a broader range of protection [3][5] - The nine-valent HPV vaccine is priced at 499 yuan per dose, which is less than half the cost of imported alternatives, making it more accessible [3] Group 3: Production and Safety - The domestic vaccine manufacturer, Wantai Biological Pharmacy, has produced over 100 million doses of the HPV vaccine, all of which have passed national quality checks [4] - Clinical studies have shown that the domestic nine-valent HPV vaccine has comparable safety and efficacy to imported products, with a 100% seroconversion rate for all HPV types tested [5] - The successful launch of the domestic nine-valent HPV vaccine is expected to alleviate supply shortages and enhance vaccination willingness among eligible women, contributing to the goal of eliminating cervical cancer by 2050 [5]

Group 1 - The Chinese government plans to include HPV vaccination services for eligible girls in the national immunization program to enhance women's health protection [1][2] - The first domestic nine-valent HPV vaccine was approved by the National Medical Products Administration in June, breaking the long-standing market monopoly of foreign products [2] - The WHO has set a target for 90% of girls to complete HPV vaccination by the age of 15 by 2030 as part of its strategy to accelerate the elimination of cervical cancer [2][3] Group 2 - The "Action Plan" aims to pilot HPV vaccination services for eligible girls by 2025, with cervical cancer screening rates for eligible women reaching 50% and treatment rates for cervical cancer and precancerous lesions at 90% [3][4] - By 2030, the plan targets a 70% cervical cancer screening rate and maintaining a 90% treatment rate for patients [3] - The government has initiated free vaccination programs for eligible girls in 17 provinces and regions, including Hainan, Fujian, and Guangdong [4][5]

Core Viewpoint - The article discusses the significant expansion of the national immunization program in China, with the inclusion of the HPV vaccine aimed at protecting women's health, particularly targeting school-aged girls [3][4]. Group 1: HPV Vaccine Inclusion - The HPV vaccine will be added to the national immunization program, focusing on the bivalent vaccine for school-aged girls [3]. - This marks a shift from a child-centric vaccination approach to a "lifecycle vaccination" strategy [3]. - The bivalent vaccine primarily targets HPV types 16 and 18, which account for 70%-80% of cervical cancer cases [3][4]. Group 2: Cervical Cancer Statistics - Cervical cancer is the second most common malignancy among women globally, with China accounting for 23% of cases and 16% of deaths worldwide [4]. - Nearly all cervical cancer cases (99.7%) are linked to HPV infection, which can lead to cervical cancer if persistent [4]. Group 3: Government Initiatives - The Chinese government has been promoting free HPV vaccination for eligible girls, with 18 provinces and several cities already implementing this initiative [5][6]. - Approximately 60% of eligible girls in China are now covered by the free vaccination policy [5]. Group 4: Vaccine Accessibility and Cost - The production and research capabilities for HPV vaccines in China have significantly improved since 2021, with two domestic bivalent vaccines approved for use [7]. - The price of the HPV vaccine has dropped dramatically, with the lowest bid now at 27.5 yuan per dose, less than one-tenth of the initial price [7]. Group 5: Comprehensive Prevention Strategy - The successful inclusion of the HPV vaccine in the national immunization program is expected to enhance the integration of primary and secondary prevention strategies for cervical cancer [8]. - A comprehensive prevention strategy may include vaccination, screening, and early diagnosis and treatment [8]. Group 6: Future Directions - The national health authorities are preparing a five-year plan to narrow the gap between domestic and international immunization programs, considering the addition of new vaccines and optimizing existing vaccination schedules [9]. - The exploration of vaccine exit strategies for those not suitable for universal vaccination is also on the agenda [9].

Core Viewpoint - The National Immunization Program in China will include the HPV vaccine this year, marking a significant expansion after 17 years, aimed at protecting women's health [1][2]. Group 1: HPV Vaccine Inclusion - The HPV vaccine will be a bivalent type, primarily targeting school-aged girls, indicating a shift from childhood vaccination to a life-cycle approach [1]. - HPV types 16 and 18, which are responsible for 70%-80% of cervical cancer cases, will be the focus of the bivalent vaccine [1]. - Cervical cancer is the second leading cause of cancer-related deaths among women globally, with China accounting for 23% of cervical cancer cases and 16% of deaths worldwide [1][2]. Group 2: Government Initiatives - The Chinese government has been promoting free HPV vaccination for eligible girls, with 18 provinces and several cities already including it in public service projects, covering approximately 60% of eligible girls [2][3]. - The World Health Organization recommends that member countries include HPV vaccination in their national immunization programs, targeting girls aged 9 to 14 [2]. Group 3: Vaccine Supply and Awareness - The widespread promotion of HPV vaccination has increased public awareness and willingness to vaccinate, with 82% of surveyed individuals expressing a desire to vaccinate their daughters [3]. - The national immunization information system has achieved full coverage, enabling dynamic monitoring of HPV vaccination status [3]. Group 4: Production and Pricing - Since 2021, domestic production and research capabilities for HPV vaccines have significantly improved, with two bivalent vaccines approved and widely used [4]. - The price of the bivalent HPV vaccine has dropped significantly due to centralized procurement, with the lowest bid now at 27.5 yuan per dose, less than one-tenth of the initial price [4]. Group 5: Future Directions - The inclusion of the HPV vaccine in the national immunization program is expected to integrate with cervical cancer screening, forming a comprehensive prevention strategy [5]. - The National Health Commission is preparing a five-year plan to gradually align China's immunization program with international standards, including the addition of new vaccines and optimization of existing vaccination schedules [5].

Group 1 - The core viewpoint of the article is that Beijing has launched a free HPV vaccination program for female students entering the first year of junior high school in 2025 [1] - The program is available to over 440 vaccination clinics across the city, providing services to eligible students [1] - Eligible students must be Chinese nationals, entering junior high school in September 2025, and must not have any contraindications for vaccination [1] Group 2 - The vaccination is based on the principles of informed consent and voluntary participation [1] - Schools will organize students who wish to get vaccinated to visit designated clinics accompanied by parents or guardians [1] - The vaccine provided is a domestically produced bivalent HPV vaccine, procured through a unified bidding process by the city [1]

Group 1 - Beijing will launch free HPV vaccination for first-year female students starting in September to enhance health protection for young women [1] - The HPV vaccine is currently the most economical and effective method for preventing cervical cancer, with high protective efficacy against pre-cancerous lesions and cancers caused by HPV types 16 and 18 [1] - Eligible first-year female students, aged 9 and above, can receive the domestically procured bivalent HPV vaccine for free, following a two-dose immunization schedule [1] Group 2 - District CDCs will coordinate with local education departments to designate vaccination clinics for each school, with vaccinations primarily conducted at the school’s designated clinic [2] - Parents or guardians must accompany students to the vaccination site, and a 30-minute observation period is required post-vaccination [2] - Students wishing to self-pay for the quadrivalent or nonavalent HPV vaccines can make appointments through various platforms, provided they meet the vaccination criteria [2]

Group 1 - The core point of the article is that Beijing will launch a free HPV vaccination program for first-year female students in September 2025, targeting cervical cancer prevention [1] - Cervical cancer is a significant health threat to women, with over 90% of HPV-related cancers being cervical cancer, leading to approximately 150,000 new cases and 55,700 deaths annually in China [1] - The vaccination will be provided to eligible girls who are Chinese nationals, starting school in Beijing in September 2025, and who have no contraindications for vaccination [1] Group 2 - The vaccine to be used is a domestically produced bivalent HPV vaccine, administered in two doses according to a 0 and 6-month immunization schedule [1] - The first dose is planned to be completed by the end of October 2025, and the second dose by the end of May 2026 [1] - All approved HPV vaccines (bivalent, quadrivalent, and nonavalent) have similar immunogenicity and efficacy in preventing cervical cancer precursors and cancer caused by HPV types 16 and 18 [2]

Core Points - The article discusses the launch of a free HPV vaccination program for eligible girls in Hangzhou, Zhejiang Province, as part of a key public health initiative for 2025 [1] - HPV is a common virus that can lead to serious health issues, including cervical cancer, with 90% of cervical cancer cases linked to HPV infection [1] - The program targets girls aged 13-14, aligning with WHO recommendations for optimal vaccination timing [1][2] Group 1: Vaccination Program Details - The vaccination is specifically for girls with Zhejiang Province residency or school enrollment [2] - Eligible girls must be aged 13-14 and should not have any prior HPV vaccinations [2] - The program offers the domestic bivalent HPV vaccine, with a recommended two-dose schedule [3] Group 2: Vaccination Guidelines - The vaccination schedule suggests administering doses at 0 and 6 months, with a minimum interval of 5 months [3] - Certain health conditions, such as fever or acute diseases, may require postponement of vaccination [3] - Parents and guardians are encouraged to consult local health authorities for specific vaccination information [3]

Core Viewpoint - Shandong Province is implementing a comprehensive plan to accelerate the elimination of cervical cancer, focusing on vaccination, early screening, and treatment to significantly reduce incidence and mortality rates [3][4]. Group 1: Vaccination Efforts - The HPV vaccination program targets high-risk HPV types 16 and 18, responsible for approximately 70%-80% of cervical cancer cases, with an effectiveness rate of over 90% [3][4]. - In 2022, Shandong initiated a free vaccination program for new seventh-grade girls, successfully vaccinating 190,600 eligible girls to date [3]. Group 2: Screening Initiatives - Shandong is conducting free cervical and breast cancer screenings for women aged 35-64 in rural and low-income urban areas, with an average of 2.6 million screenings conducted annually [4]. - A professional team will provide home screening services and timely feedback on test results to enhance early detection [4]. Group 3: Treatment Protocols - Positive screening cases will undergo comprehensive follow-up, with tailored treatment plans based on disease characteristics and severity [4]. - Early-stage patients will receive medication or physical therapy, while complex cases will be managed through multidisciplinary expert consultations [4]. Group 4: Health Education and Awareness - The initiative includes extensive health education efforts, utilizing online platforms for expert-led live sessions and offline community engagement through lectures [4]. - The goal is to foster a societal focus on cervical cancer prevention and enhance public health awareness [4].